Cargando…

Trastuzumab administration during pregnancy: an update

BACKGROUND: Over than one third (28–58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrikopoulou, Angeliki, Apostolidou, Kleoniki, Chatzinikolaou, Spyridoula, Bletsa, Garyfalia, Zografos, Eleni, Dimopoulos, Meletios-Athanasios, Zagouri, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074427/ https://www.ncbi.nlm.nih.gov/pubmed/33902516 http://dx.doi.org/10.1186/s12885-021-08162-3

Ejemplares similares

Correction to: Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer
por: Zografos, Eleni, et al.
Publicado: (2022)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Prognostic role of microRNAs in breast cancer: A systematic review
por: Zografos, Eleni, et al.
Publicado: (2019)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Germline mutations in a clinic-based series of pregnancy associated breast cancer patients
por: Zografos, Eleni, et al.
Publicado: (2021)

Update Overview of the Role of Angiopoietins in Lung Cancer
por: Tsakogiannis, Dimitris, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Immune checkpoint inhibitor administration during pregnancy: a case series
por: Andrikopoulou, A., et al.
Publicado: (2021)

The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review
por: Korakiti, Anna-Maria, et al.
Publicado: (2020)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer
por: Tsakogiannis, Dimitris, et al.
Publicado: (2021)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Supportive medication in cancer during pregnancy
por: Zagouri, Flora, et al.
Publicado: (2020)

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC
por: Nikolakopoulou, Asimina, et al.
Publicado: (2022)

Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses
por: Georgakopoulou, Rebecca, et al.
Publicado: (2021)

Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy
por: Korakiti, Anna-Maria, et al.
Publicado: (2020)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
por: Liontos, Michalis, et al.
Publicado: (2021)

Pembrolizumab in endometrial cancer: Where we stand now
por: Aravantinou-Fatorou, Aikaterini, et al.
Publicado: (2021)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas
por: Tsakogiannis, Dimitris, et al.
Publicado: (2022)

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience
por: Liontos, Michalis, et al.
Publicado: (2021)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Cancer in pregnancy: disentangling treatment modalities
por: Zagouri, Flora, et al.
Publicado: (2016)

Advances in Gynecological Cancers
por: Liontos, Michalis, et al.
Publicado: (2022)

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study
por: Kalapanida, Despoina, et al.
Publicado: (2018)

Gestational trophoblastic neoplasia with retroperitoneal metastases: A fatal complication
por: Thomakos, Nikolaos, et al.
Publicado: (2010)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Defining Oligometastatic Bladder Cancer: A Systematic Review
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Treatment of early uterine sarcomas: disentangling adjuvant modalities
por: Zagouri, Flora, et al.
Publicado: (2009)

Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors
por: Papadopetraki, Argyro, et al.
Publicado: (2022)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_84ns6m004e5nb5u332k4rfk6r7